This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.

Abstract Submission


Abstract Submission Opens: OPEN NOW!

Abstract Submission Closes: Wednesday, April 14, 2021

Confirmation Letter Sent: Mid-May 2021


  • Abstracts must be submitted electronically using the official online submission form
  • Abstracts must identify the presenting author along with email address 
  • Please use standard abbreviations. Place special or unusual abbreviations in parenthesis after the full word when it appears for the first time
  • Errors, misspellings, and incorrect abbreviations will not be corrected
  • An individual may submit more than one (1) abstract. One official online submission is required for each abstract
  • Edits to submitted abstracts may be made up to the submission deadline. Instructions for making edits can be found on the submission site




During the online abstract submission, authors will be requested to select their preferred method of presentation: Oral/ Poster Presentation or Poster only Presentation.

Presentation method preferences will be considered during the review process.


Themes (topics) for each of the sessions are listed below. Please submit your abstract on either HCV, Flaviviruses or any of the related viruses under one of the following themes:

  • Innate Immunity/Virus-Host Interaction
  • Liver Inflammation, Viral Pathogenesis, and Carcinogenesis
  • Viral Life Cycle 1 (Entry, Replication)
  • Viral Life Cycle 2 (Translation, Assembly)
  • Tools for HCV Elimination: Diagnostics, Sequencing and Beyond
  • Animal Models, Organoids and Replication Systems
  • Adaptive Immunity
  • Antivirals: Challenges and New Frontiers
  • Vaccines
  • SARS-CoV-2 and HCV Interaction
The abstract review committee reserves the right to reassign submitted abstracts to a different session.


Please adhere to the following formatting guidelines when submitting your abstracts for HCV2021. Abstracts that are not correctly formatted will not be reviewed.

  • The abstract title should not exceed 300 characters
  • The abstracts should not exceed 300 words
  • Each abstract is allowed to include a maximum of one (1) caption (figure or table) but this is not a requirement. Minimize the use of charts and graphics as this detail is not used to evaluate the merit of your abstract
  • There is no restriction on your abstract structure, but we recommended the following:
    • Title
    • Background
    • Purpose
    • Method(s)
    • Result(s)
    • Conclusion(s)


Presenting authors will be notified of their acceptance status on or before Mid-May 2021. Presenting authors must inform any co-author(s) of acceptance. The organizing committee reserves the right to accept or decline any submissions and to select the presentation format (oral or poster).


The presenting authors of abstracts selected for oral presentation will be required to complete and submit a Disclosure of Conflicts of Interest form after they are invited to present. Disclosures are due on or before the RSVP deadline.


The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events.

If you have any questions about the abstract submission process, please email us at :